Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Détails bibliographiques
Auteur principal:	Flora, Sanzida Alam
Autres auteurs:	Azam, Faruque
Format:	Thèse
Langue:	English
Publié:	Brac University 2024
Sujets:	NSCLC Tyrosine kinase inhibitor Efficacy endpoints Cancer therapy Lung cancer Lung cancer > Treatment Protein-tyrosine kinase > Inhibitors > Therapeutic use
Accès en ligne:	http://hdl.handle.net/10361/23693

Documents similaires

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
par: Khan, Muidul Hasan
Publié: (2024)

Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
par: Paul, Pulock
Publié: (2024)

Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
par: Rahman, Tasnim
Publié: (2024)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
par: Sorno, Rubina Haque
Publié: (2024)

Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
par: Hoque, Ismoth Ara
Publié: (2024)

Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
par: Karim, Samia Binte
Publié: (2024)

Immunotherapy in the Management of Lung Cancer
par: Tasnim, Humayra
Publié: (2022)

Molecules associated with the development of lung cancer
par: Rahman, Adree, et autres
Publié: (2023)

Protein biomarkers for Lung Cancer: a bioinformatic approach
par: Jeba, Joynob
Publié: (2017)

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
par: Meem, Manila
Publié: (2023)

A review on targeted therapies for lung cancer
par: Ashraf, Anushey
Publié: (2023)

Potential of liposomes for the treatment of lung cancer- a review
par: Mim, Shanzida
Publié: (2023)

A review on recent advances in drugs for lung cancer treatment
par: Noor, Fouzia
Publié: (2024)

A review on potential of PARP inhibitors in the treatment of prostate cancer
par: Islam, Saidul
Publié: (2022)

Computational insights into molecular docking strategies for non-small cell lung cancer drug discovery
par: Das, Reshita
Publié: (2024)

A cross-sectional study on risk factors, symptoms, treatment and management strategies of lung cancer in a tertiary care cancer hospital of Bangladesh
par: Pial, Sazia Afrin
Publié: (2018)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
par: Razna, Amrin Islam
Publié: (2019)

Pooled analysis of progression-free survival and overall survival in phase II clinical trials of breast cancer
par: Shobnam, Sohana
Publié: (2024)

A case study of lung cancer patients in term of various risk factors in context of Bangladesh
par: Shabnam, Musharrat
Publié: (2018)

Bioinformatics analyses of key regulators of NF-κB pathway in relation with small cell lung carcinoma
par: Zangmo, Thinley
Publié: (2024)

Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
par: Tania, Umme
Publié: (2023)

In silico modelling and structural dynamics of PSY1R kinase domain and its interaction with SERK1 kinase
par: Ruhee, Noshin Nawer
Publié: (2022)

RIPK pathway, as a potential target, for cancer treatment - a review
par: Jahan, Nusrat
Publié: (2024)

An overview of the clinical management and challenges of treatments for the patients diagnosed with COVID-19 and lung carcinoma
par: Bristy, Israt Zerin
Publié: (2021)

Lung cancer detection and classification using machine learning
par: Arefin, Mahbubul, et autres
Publié: (2023)

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
par: Karim, Azrin
Publié: (2024)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
par: Haque, Mushfiqul
Publié: (2019)

Score based risk assessment of lung cancer and its evaluation for Bangladeshi people
par: Mukti, Roushney Fatima, et autres
Publié: (2016)

A review on insulin-producing beta cell: regenerative role of drugs acting on DYRK1A, GLP-1 and DPP-4 receptors
par: Mahmood, Nyrit
Publié: (2021)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
par: Ratu, Tabassum
Publié: (2024)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
par: Mirza, Maisa Tasnim
Publié: (2023)

Lung cancer immunosuppression and therapeutic targeting of myeloid- derived suppressor cells
par: Nandy, Aditi
Publié: (2022)

Statistics and informatics in molecular cancer research

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
par: Hasan, Amit
Publié: (2024)

Identification of FAP inhibitors using in silico simulation study
par: Deeba, Maliha Tasnim
Publié: (2018)

Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
par: Abir, Shifaty Nur
Publié: (2024)

Evaluation of genetics of cancer predisposition in patients and efficacy of various chemotherapeutic drugs in Bangladesh
par: Hossain, Safa Binte
Publié: (2019)

Recent advances in Cancer treatment targeting autophagy and future aspects
par: Emon, Kamrul Hasan
Publié: (2022)

Cancer risk factors: a critical review
par: Tabassum, Tahsina
Publié: (2017)

Survey on patients undergoing treatments for cervical, endometrial and ovarian cancer
par: Nawar, Anika
Publié: (2019)